MarketCapExport financials
Denali Therapeutics (DNLI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Denali Therapeutics Income Statement 2025-2011 | DNLI
Brief overview of income trends at Denali Therapeutics
The overview follows changes across a five-year period. Revenue reported by Denali Therapeutics was $129 million at the beginning of the period and $331 million at the end. The five-year change reached +155.9%, while CAGR stood at 20.7%. The annual growth rate indicates an exceptionally strong top-line trend.
EBITDA was −$39 million at the beginning and −$180 million at the end of the period (−362%). The operating result developed less favorably than sales. The EBITDA share of revenue changed from −30.2% to −54.4%. A lower EBITDA share weakens the quality of the result.
The final result was −$36.2 million initially and −$145 million in the final year. Larger losses indicate rising pressure on the business.
The market value of the business moved from $1.8 billion to $2.5 billion, or +45%. Investors responded cautiously to the improvement in the business.
Overall conclusion
Signs of deterioration dominate the five-year picture. The positive side is supported by sales growth. The overall view is constrained by lower net income, a declining EBITDA margin and a low EBITDA margin. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Denali Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.41 B | 3.04 B | 2.54 B | 3.36 B | 3.96 B | 7.82 B | 2.23 B | 1.75 B | 354 M | - | - | - | - | - | - |
Shares |
173 M | 164 M | 137 M | 126 M | 122 M | 109 M | 95.6 M | 92.6 M | 15 M | - | - | - | - | - | - |
Historical Prices |
14 | 18.5 | 18.5 | 26.8 | 32.6 | 71.8 | 19.8 | 21.8 | 22.9 | - | - | - | - | - | - |
Net Income |
-513 M | -423 M | -145 M | -326 M | -291 M | 71.1 M | -198 M | -36.2 M | -88.2 M | -86.7 M | -16.8 M | - | - | - | - |
Revenue |
- | - | 331 M | 108 M | 48.7 M | 336 M | 26.7 M | 129 M | - | - | - | - | - | - | - |
Operating Income |
-555 M | -487 M | -197 M | -341 M | -296 M | 62.7 M | -213 M | -46.4 M | -90.1 M | -87.4 M | - | - | - | - | - |
EBITDA |
-544 M | -480 M | -180 M | -330 M | -287 M | 71.2 M | -205 M | -39 M | -87.1 M | -86 M | -16.6 M | - | - | - | - |
Operating Expenses |
555 M | 502 M | 527 M | 449 M | 344 M | 273 M | 240 M | 176 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
137 M | 105 M | 103 M | 90.5 M | 79.1 M | 60.3 M | 46.5 M | 32.3 M | 15.7 M | 11.7 M | 5.11 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Denali Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
187 M | 187 M | 172 M | 171 M | 171 M | 144 M | 169 M | 169 M | 149 M | 138 M | 138 M | 137 M | 137 M | 136 M | 123 M | 123 M | 123 M | 122 M | 122 M | 121 M | 121 M | 121 M | 107 M | 106 M | 102 M | 96.1 M | 95.9 M | 95.5 M | 95 M | 94.3 M | 93.7 M | 92.9 M | 89.6 M | 87.5 M | 10.2 M | 9.67 M | 9.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-128 M | -128 M | -127 M | -124 M | -133 M | - | -107 M | -99 M | -102 M | - | -99.4 M | 183 M | -110 M | - | -103 M | -58.8 M | -65.2 M | - | -84.6 M | -60.7 M | -70 M | - | -58.2 M | -58.8 M | -56.8 M | -54 M | -46.3 M | -58.3 M | -39 M | 77.5 M | -35.4 M | -54.7 M | -23.7 M | -22.9 M | -21.8 M | -22.1 M | -21.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
3.6 M | - | - | - | - | - | - | - | - | - | 1.27 M | 294 M | 35.1 M | - | 3.56 M | 52.5 M | 42.1 M | - | 5.28 M | 22.9 M | 7.92 M | - | 9.39 M | 5.85 M | 3.6 M | 4.67 M | 13.6 M | 4.2 M | 4.2 M | 126 M | 1.2 M | 1.65 M | 641 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
93 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-131 M | -137 M | -137 M | -135 M | -146 M | - | -123 M | -117 M | -118 M | - | -114 M | 170 M | -121 M | - | -107 M | -61.4 M | -66.5 M | - | -85.6 M | -61.8 M | -71.2 M | - | -60.1 M | -61.3 M | -60 M | -57.8 M | -50.2 M | -62.8 M | -42.5 M | 74.7 M | -38 M | -57.4 M | -25.7 M | -23.5 M | -22.3 M | -22.6 M | -21.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-124 M | -135 M | - | - | -143 M | - | - | - | -116 M | - | - | - | -111 M | - | -101 M | -57.3 M | -64.4 M | - | -79.1 M | -57.5 M | -69.1 M | - | -53.7 M | -57 M | -57.9 M | -57.8 M | -44.2 M | -58.7 M | -40.1 M | 74.7 M | -32.9 M | -54.7 M | -24.9 M | -23.5 M | -20 M | -21.1 M | -21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 137 M | 137 M | 135 M | 146 M | - | 123 M | 117 M | 132 M | - | 115 M | 124 M | 156 M | - | 111 M | 114 M | 109 M | - | 90.9 M | 84.8 M | 79.1 M | - | 69.5 M | 67.1 M | 63.6 M | - | 63.8 M | 67 M | 46.7 M | - | 39.2 M | 59 M | 26.4 M | - | 22.3 M | 22.6 M | 21.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
36.3 M | 33.5 M | 35.5 M | 32.3 M | 29.4 M | - | 24.9 M | 25.2 M | 25.2 M | - | 25.3 M | 26.1 M | 27.1 M | - | 23.3 M | 21.2 M | 22.5 M | - | 19.3 M | 19 M | 18.9 M | - | 15.8 M | 14 M | 12.6 M | - | 11.2 M | 15.1 M | 9.31 M | - | 8.84 M | 6.9 M | 5.57 M | - | 3.77 M | 3.56 M | 3.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Denali Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Niderland
France
Israel
Australia
Britain
